Published in Genes Dev on November 01, 2004
Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature (2006) 8.06
Four faces of cellular senescence. J Cell Biol (2011) 6.86
p53--a Jack of all trades but master of none. Nat Rev Cancer (2009) 2.96
Peto's Paradox: evolution's prescription for cancer prevention. Trends Ecol Evol (2011) 2.48
DNA damage checkpoints in stem cells, ageing and cancer. Nat Rev Mol Cell Biol (2012) 2.39
Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression. Genes Dev (2006) 2.20
Aging and cancer resistance in lymphoid progenitors are linked processes conferred by p16Ink4a and Arf. Genes Dev (2008) 1.79
Mechanisms that regulate stem cell aging and life span. Cell Stem Cell (2013) 1.73
Oncogenicity of the developmental transcription factor Sox9. Cancer Res (2012) 1.55
Puma is required for p53-induced depletion of adult stem cells. Nat Cell Biol (2010) 1.41
Pathologies associated with the p53 response. Cold Spring Harb Perspect Biol (2010) 1.40
Increased p53 activity does not accelerate telomere-driven ageing. EMBO Rep (2006) 1.30
Inflammation and p53: A Tale of Two Stresses. Genes Cancer (2011) 1.27
Molecular characterization of spontaneous mesenchymal stem cell transformation. PLoS One (2008) 1.26
Limited role of murine ATM in oncogene-induced senescence and p53-dependent tumor suppression. PLoS One (2009) 1.22
Reduced expression of MYC increases longevity and enhances healthspan. Cell (2015) 1.22
The p16INK4a tumor suppressor controls p21WAF1 induction in response to ultraviolet light. Nucleic Acids Res (2006) 1.15
An extra allele of Chk1 limits oncogene-induced replicative stress and promotes transformation. J Exp Med (2012) 1.15
Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo. Mol Ther (2014) 1.13
Antiviral action of the tumor suppressor ARF. EMBO J (2006) 1.02
mTORC1 and p53: clash of the gods? Cell Cycle (2013) 0.98
G6PD protects from oxidative damage and improves healthspan in mice. Nat Commun (2016) 0.94
Models of reactive oxygen species in cancer. Drug Discov Today Dis Models (2007) 0.93
Residues in the alternative reading frame tumor suppressor that influence its stability and p53-independent activities. Exp Cell Res (2009) 0.91
Breast cancer, stem cells and prospects for therapy. Breast Cancer Res (2006) 0.90
P14ARF inhibits human glioblastoma-induced angiogenesis by upregulating the expression of TIMP3. J Clin Invest (2012) 0.90
Senescence regulation by the p53 protein family. Methods Mol Biol (2013) 0.88
A strategy to study tyrosinase transgenes in mouse melanocytes. BMC Cell Biol (2005) 0.88
Mice deficient in Rbm38, a target of the p53 family, are susceptible to accelerated aging and spontaneous tumors. Proc Natl Acad Sci U S A (2014) 0.88
INK4 locus of the tumor-resistant rodent, the naked mole rat, expresses a functional p15/p16 hybrid isoform. Proc Natl Acad Sci U S A (2014) 0.87
The scientific quest for lasting youth: prospects for curing aging. Rejuvenation Res (2014) 0.87
Significance of cellular senescence in aging and cancer. Cancer Res Treat (2009) 0.86
Transgenic and knockout mice models to reveal the functions of tumor suppressor genes. Clin Med Insights Oncol (2011) 0.85
RNA polymerase III transcription is repressed in response to the tumour suppressor ARF. Nucleic Acids Res (2007) 0.84
Dmp1α inhibits HER2/neu-induced mammary tumorigenesis. PLoS One (2013) 0.84
Increased gene dosage of Ink4/Arf and p53 delays age-associated central nervous system functional decline. Aging Cell (2015) 0.80
Loss of p53-mediated cell-cycle arrest, senescence and apoptosis promotes genomic instability and premature aging. Oncotarget (2016) 0.79
Dynamics of ARF regulation that control senescence and cancer. BMB Rep (2016) 0.75
Stem cell therapeutics--reality versus hype and hope. J Assist Reprod Genet (2010) 0.75
Clinical applications of mouse models for breast cancer engaging HER2/neu. Integr Cancer Sci Ther (2016) 0.75
Transcriptional Activation of p53 during Cold Induced Torpor in the 13-Lined Ground Squirrel Ictidomys tridecemlineatus. Biochem Res Int (2015) 0.75
Increased Arf/p53 activity in stem cells, aging and cancer. Aging Cell (2017) 0.75
Senescence in Health and Disease. Cell (2017) 0.75
Detection of large-scale variation in the human genome. Nat Genet (2004) 49.18
Large-scale copy number polymorphism in the human genome. Science (2004) 34.64
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell (1997) 29.13
Allelic variation in human gene expression. Science (2002) 11.42
Role of the INK4a locus in tumor suppression and cell mortality. Cell (1996) 11.41
p53 mutant mice that display early ageing-associated phenotypes. Nature (2002) 10.05
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev (1998) 9.03
Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev (2003) 8.00
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature (2001) 7.06
Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene (1997) 5.64
Allelic variation in gene expression is common in the human genome. Genome Res (2003) 5.50
p19ARF links the tumour suppressor p53 to Ras. Nature (1998) 4.89
To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer (2001) 4.86
E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev (1998) 4.60
Modulation of mammalian life span by the short isoform of p53. Genes Dev (2004) 4.52
The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta (1998) 4.45
"Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J (2002) 4.17
Putting the stress on senescence. Curr Opin Cell Biol (2001) 3.41
Small changes in expression affect predisposition to tumorigenesis. Nat Genet (2001) 3.37
Cancer and ageing: rival demons? Nat Rev Cancer (2003) 3.25
Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions. Genes Dev (2001) 3.16
Different telomere damage signaling pathways in human and mouse cells. EMBO J (2002) 2.87
Gene copy number regulates the production of the human chemokine CCL3-L1. Eur J Immunol (2002) 2.24
Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. EMBO J (2000) 2.21
The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis. Oncogene (2004) 2.14
Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras. Oncogene (1999) 2.00
The molecular basis of brown, an old mouse mutation, and of an induced revertant to wild type. Genetics (1990) 1.66
The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development. Proc Natl Acad Sci U S A (2002) 1.59
Induction of senescence by oncogenic Ras. Methods Enzymol (2001) 1.52
Cancer as a complex genetic trait: tumor susceptibility in humans and mouse models. Cell (2002) 1.46
Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo. Oncogene (2003) 1.29
Accumulation of p16INK4a in mouse fibroblasts as a function of replicative senescence and not of retinoblastoma gene status. Oncogene (1997) 1.27
Invasive melanoma in Cdk4-targeted mice. Proc Natl Acad Sci U S A (2001) 1.24
As normal as normal can be? Nat Genet (2004) 1.17
Allelic variations in gene expression. Curr Opin Oncol (2004) 1.16
p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression. J Natl Cancer Inst (2003) 1.16
Pulmonary metastases from autochthonous 3-methylcholanthrene-induced murine tumors. J Natl Cancer Inst (1979) 1.13
Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility. Mol Cell Biol (2001) 0.98
mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol (2010) 21.16
International network of cancer genome projects. Nature (2010) 20.35
The hallmarks of aging. Cell (2013) 14.29
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18
Tumour biology: senescence in premalignant tumours. Nature (2005) 10.15
Cellular senescence in cancer and aging. Cell (2007) 9.04
A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature (2009) 7.96
mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science (2011) 7.55
The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature (2009) 7.39
Senescence in tumours: evidence from mice and humans. Nat Rev Cancer (2010) 6.34
Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A (2008) 5.21
Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell (2003) 5.17
A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev (2007) 5.07
Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. Cell Stem Cell (2009) 4.59
The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell (2008) 4.48
The common biology of cancer and ageing. Nature (2007) 4.28
"Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J (2002) 4.17
Delayed ageing through damage protection by the Arf/p53 pathway. Nature (2007) 3.87
Mature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62. Cell Metab (2006) 3.22
Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun (2010) 2.97
Increased telomere fragility and fusions resulting from TRF1 deficiency lead to degenerative pathologies and increased cancer in mice. Genes Dev (2009) 2.91
The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer (2006) 2.85
Telomerase reverse transcriptase delays aging in cancer-resistant mice. Cell (2008) 2.85
SNAI1 is required for tumor growth and lymph node metastasis of human breast carcinoma MDA-MB-231 cells. Cancer Res (2007) 2.80
Programmed cell senescence during mammalian embryonic development. Cell (2013) 2.78
The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell (2004) 2.65
Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell (2011) 2.56
Oncogenic activity of Cdc6 through repression of the INK4/ARF locus. Nature (2006) 2.51
The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression. Nat Genet (2011) 2.47
Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature (2013) 2.47
Epigenetic regulation of Nanog expression by Ezh2 in pluripotent stem cells. Cell Cycle (2011) 2.45
A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA methyltransferases. Nat Struct Mol Biol (2008) 2.43
Depletion of ribosomal protein L37 occurs in response to DNA damage and activates p53 through the L11/MDM2 pathway. Cell Cycle (2010) 2.41
PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med (2005) 2.28
XPF nuclease-dependent telomere loss and increased DNA damage in mice overexpressing TRF2 result in premature aging and cancer. Nat Genet (2005) 2.26
Suv4-20h deficiency results in telomere elongation and derepression of telomere recombination. J Cell Biol (2007) 2.24
TPP1 is required for TERT recruitment, telomere elongation during nuclear reprogramming, and normal skin development in mice. Dev Cell (2010) 2.24
p53: guardian of the genome and policeman of the oncogenes. Cell Cycle (2007) 2.23
High-throughput telomere length quantification by FISH and its application to human population studies. Proc Natl Acad Sci U S A (2007) 2.15
A minimally invasive assay for individual assessment of the ATM/CHEK2/p53 pathway activity. Cell Cycle (2011) 2.13
SIRT1: recent lessons from mouse models. Nat Rev Cancer (2010) 2.07
Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin. Cancer Res (2007) 1.97
miR-33-mediated downregulation of p53 controls hematopoietic stem cell self-renewal. Cell Cycle (2010) 1.95
Tumour biology: Policing of oncogene activity by p53. Nature (2006) 1.86
Pten positively regulates brown adipose function, energy expenditure, and longevity. Cell Metab (2012) 1.81
IgA antibodies against β2 glycoprotein I in hemodialysis patients are an independent risk factor for mortality. Kidney Int (2012) 1.59
Nephrin deficiency activates NF-kappaB and promotes glomerular injury. J Am Soc Nephrol (2009) 1.57
Oncogenicity of the developmental transcription factor Sox9. Cancer Res (2012) 1.55
Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. J Hypertens (2005) 1.53
A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA methyltransferases. Nat Struct Mol Biol (2008) 1.51
Mechanistic principles of chromatin remodeling guided by siRNAs and miRNAs. Cell Cycle (2008) 1.50
Sirtuin 1 regulation of developmental genes during differentiation of stem cells. Proc Natl Acad Sci U S A (2010) 1.48
Polycomb mediated epigenetic silencing and replication timing at the INK4a/ARF locus during senescence. PLoS One (2009) 1.48
SIRT1 contributes to telomere maintenance and augments global homologous recombination. J Cell Biol (2010) 1.48
Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res (2007) 1.45
WNT16B is a new marker of cellular senescence that regulates p53 activity and the phosphoinositide 3-kinase/AKT pathway. Cancer Res (2009) 1.39
The Arf/p53 pathway in cancer and aging. Cancer Res (2008) 1.37
Tumour-suppression activity of the proapoptotic regulator Par4. EMBO Rep (2005) 1.36
Telomerase abrogation dramatically accelerates TRF2-induced epithelial carcinogenesis. Genes Dev (2007) 1.33
Cooperation between p53 mutation and high telomerase transgenic expression in spontaneous cancer development. Mol Cell Biol (2002) 1.32
Genome-wide CTCF distribution in vertebrates defines equivalent sites that aid the identification of disease-associated genes. Nat Struct Mol Biol (2011) 1.31
RAP1 protects from obesity through its extratelomeric role regulating gene expression. Cell Rep (2013) 1.31
Increased p53 activity does not accelerate telomere-driven ageing. EMBO Rep (2006) 1.30
The rate of increase of short telomeres predicts longevity in mammals. Cell Rep (2012) 1.26
Par-4 inhibits Akt and suppresses Ras-induced lung tumorigenesis. EMBO J (2008) 1.25
Genetic inactivation of Par4 results in hyperactivation of NF-kappaB and impairment of JNK and p38. EMBO Rep (2003) 1.24
p27(Kip1) directly represses Sox2 during embryonic stem cell differentiation. Cell Stem Cell (2012) 1.23
Limited role of murine ATM in oncogene-induced senescence and p53-dependent tumor suppression. PLoS One (2009) 1.22
Cold-inducible RNA-binding protein bypasses replicative senescence in primary cells through extracellular signal-regulated kinase 1 and 2 activation. Mol Cell Biol (2009) 1.20
Snail1 is a transcriptional effector of FGFR3 signaling during chondrogenesis and achondroplasias. Dev Cell (2007) 1.19
PTEN in cancer, metabolism, and aging. Trends Endocrinol Metab (2012) 1.18
Shorter telomeres, accelerated ageing and increased lymphoma in DNA-PKcs-deficient mice. EMBO Rep (2004) 1.18
Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms. J Clin Invest (2005) 1.18